Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists

By Thibonnier M.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 5, 1998-05 ,pp. : 729-740

Informa Healthcare

Access to resources Recommend Favorite

Recent discovery and development of non-peptide vasopressin V2 receptor agonists

By Kondo Kazumi  

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 8, 2002-08 ,pp. : 1249-1258

Informa Healthcare

Access to resources Recommend Favorite

[Arg 8 ]Vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists

By Bax W.A.   Van der Graaf P.H.   Stam W.B.   Bos E.   Nisato D.   Saxena P.R.  

European Journal of Pharmacology, Vol. 285, Iss. 2, 1995-10 ,pp. : 199-202

Elsevier

Access to resources Recommend Favorite

Non-Peptide Vasopressin V1b Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related Disorders

By  

Current Pharmaceutical Design, Vol. 11, Iss. 12, 2005-05 ,pp. : 1549-1559

Bentham Science Publishers

Access to resources Recommend Favorite

Pyrazinobenzodiazepines as Potent Nonpeptide Vasopressin Receptor Antagonists

By  

Letters in Drug Design & Discovery, Vol. 2, Iss. 3, 2005-05 ,pp. : 219-223

Bentham Science Publishers

Access to resources Recommend Favorite